ArriVent BioPharma, Inc. Common Stock Detailed Financials

Full historical quarterly statements

Metric	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	0	0	0	0	0	0	0	0
Cost of Goods Sold	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0
R&D Expenses	37.6M	32.2M	32.2M	27.7M	61.3M	20.2M	20.1M	21.8M
Operating Expenses	46.1M	38.8M	38.3M	33.6M	66.8M	23.7M	24.2M	25.7M
Operating Income	-46.1M	-38.8M	-38.3M	-33.6M	-66.8M	-23.7M	-24.2M	-25.7M
Other Income / Gains	2.8M	3.3M	3.3M	2.2M	2.4M	3.1M	3.7M	3.8M
Net Income	-43.3M	-35.5M	-35.0M	-31.4M	-64.4M	-20.6M	-20.6M	-21.9M
EPS (Diluted)	-0.96	-0.84	-0.83	-0.90	-1.90	-0.61	-0.61	-0.65
Reported Currency	USD	USD	USD	USD	USD	USD	USD	USD
Gross Profit Ratio	0	0	0	0	0	0	0	0
General And Administrative Expenses	8.5M	6.6M	6.1M	5.9M	5.5M	3.5M	4.1M	3.9M
Selling And Marketing Expenses	0	0	0	0	0	0	0	0
Selling General And Administrative Expenses	8.5M	6.6M	6.1M	5.9M	5.5M	3.5M	4.1M	3.9M
Other Expenses	0	0	0	0	0	0	0	0
Cost And Expenses	46.1M	38.8M	38.3M	33.6M	66.8M	23.7M	24.2M	25.7M
Interest Income	2.8M	3.3M	3.3M	2.2M	2.4M	3.1M	3.7M	3.8M
Interest Expense	0	0	0	0	0	0	0	0
Depreciation And Amortization	0	0	0	0	0	0	0	0
Ebitda	-43.3M	-35.5M	-35.0M	-31.4M	-64.4M	-20.6M	-20.6M	-21.9M
Ebitdaratio	0	0	0	0	0	0	0	0
Operating Income Ratio	0	0	0	0	0	0	0	0
Income Before Tax	-43.3M	-35.5M	-35.0M	-31.4M	-64.4M	-20.6M	-20.6M	-21.9M
Income Before Tax Ratio	0	0	0	0	0	0	0	0
Income Tax Expense	0	0	0	0	0	0	0	0
Net Income Ratio	0	0	0	0	0	0	0	0
Epsdiluted	-0.96	-0.84	-0.83	-0.90	-1.90	-0.61	-0.61	-0.65
Weighted Average Shs Out	45.1M	38.5M	41.9M	35.0M	33.9M	33.6M	33.6M	33.5M
Weighted Average Shs Out Dil	45.1M	38.5M	41.9M	35.0M	33.9M	33.6M	33.6M	33.5M